Sanjay Reddy
Internal Medicine · Longview, TXNPI 1649459595
Payments from drug & device makers
Across 309 payments — averaging $14.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$914
- Novo Nordisk$526
- Pfizer$336
- AbbVie$326
- Merck$253
- Lilly USA, LLC$211
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,47099%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 76 | $914 |
| Novo Nordisk | 41 | $526 |
| Pfizer | 18 | $336 |
| AbbVie(2 entities) | 25 | $326 |
| Merck | 18 | $253 |
| Lilly USA, LLC | 15 | $211 |
| Amgen | 13 | $175 |
| Bayer | 11 | $170 |
| Johnson & Johnson | 11 | $160 |
| AstraZeneca | 10 | $157 |
| Currax Pharmaceuticals LLC | 9 | $139 |
| Boehringer Ingelheim | 7 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $117 |
| Novartis | 5 | $108 |
| Sumitomo Pharma America, Inc. | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 5 | $66 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $43 |
| Eisai Inc. | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Boston Scientific | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Almatica Pharma LLC | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Lundbeck LLC | 1 | $29 |
| Cashflow Solutions, LLC | 1 | $29 |
| Dexcom, Inc. | 1 | $25 |
| Abiomed | 1 | $23 |
| Abbott | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Biogen | 1 | $16 |
| Si-bone, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| GE HealthCare | 1 | $15 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,495 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 219 | $232,893 |
| EliquisApixaban | 232 | $138,708 |
| OzempicSemaglutide | 109 | $117,014 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $101,320 |
| XareltoRivaroxaban | 113 | $64,005 |
| TradjentaLinagliptin | 98 | $56,567 |
| JardianceEmpagliflozin | 60 | $49,405 |
| FarxigaDapagliflozin Propanediol | 46 | $42,368 |
| JanuviaSitagliptin Phosphate | 41 | $21,021 |
| LinzessLinaclotide | 28 | $19,660 |
| RybelsusSemaglutide | 12 | $18,625 |
| Repatha SureclickEvolocumab | 27 | $16,964 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $16,167 |
| Atorvastatin Calcium | 1,342 | $12,088 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $12,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $211 | $232,893219 claims |
| PfizerEliquis | $336 | $138,708232 claims |
| Novo NordiskOzempic, Rybelsus | $526 | $135,639121 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $914 | $117,487179 claims |
| Boehringer IngelheimTradjenta, Jardiance | $127 | $105,972158 claims |
| Johnson & JohnsonXarelto | $160 | $64,005113 claims |
| AstraZenecaFarxiga | $157 | $42,36846 claims |
| MerckJanuvia, Janumet Xr | $253 | $26,82652 claims |
| AbbVieLinzess, Namzaric | $326 | $23,09540 claims |
| NovartisEntresto | $108 | $10,31213 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $66 | $3,45811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Longview
- Kathleen HarrisLongview$3.1M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.